Maria Letizia Barreca

List of Publications by Year
in descending order

95 papers	3,573 citations	109321 35 h-index	149698 56 g-index
102 all docs	102 docs citations	102 times ranked	4087 citing authors

#	Article	IF	Citations
1	5-Arylidene-2-imino-4-thiazolidinones: Design and synthesis of novel anti-inflammatory agents. Bioorganic and Medicinal Chemistry, 2005, 13, 4243-4252.	3.0	246
2	Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1793-1796.	2.2	214
3	Pharmacophore-Based Design of HIV-1 Integrase Strand-Transfer Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 7084-7088.	6.4	160
4	Design, Synthesis, Structureâˆ'Activity Relationships, and Molecular Modeling Studies of 2,3-Diaryl-1,3-thiazolidin-4-ones as Potent Anti-HIV Agents. Journal of Medicinal Chemistry, 2002, 45, 5410-5413.	6.4	151
5	A 1,8-Naphthyridone Derivative Targets the HIV-1 Tat-Mediated Transcription and Potently Inhibits the HIV-1 Replication. Journal of Medicinal Chemistry, 2010, 53, 641-648.	6.4	122
6	Design, Synthesis, and Biological Evaluation of a Series of 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain. Journal of Medicinal Chemistry, 2008, 51, 7717-7730.	6.4	115
7	Pharmacophoreâ€Based Discovery of Smallâ€Molecule Inhibitors of Proteinâ€"Protein Interactions between HIVâ€1 Integrase and Cellular Cofactor LEDGF/p75. ChemMedChem, 2009, 4, 1311-1316.	3.2	98
8	Discovery of a Novel and Highly Potent Noncompetitive AMPA Receptor Antagonist. Journal of Medicinal Chemistry, 2003, 46, 197-200.	6.4	80
9	Molecular Dynamics Studies of the Wild-Type and Double Mutant HIV-1 Integrase Complexed with the 5CITEP Inhibitor: Mechanism for Inhibition and Drug Resistance. Biophysical Journal, 2003, 84, 1450-1463.	0.5	78
10	AMPA Receptor Antagonists as Potential Anticonvulsant Drugs. Current Topics in Medicinal Chemistry, 2005, 5, 31-42.	2.1	70
11	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1956-1960.	2.2	70
12	A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model. PLoS Pathogens, 2012, 8, e1002774.	4.7	70
13	Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). Bioorganic and Medicinal Chemistry, 1999, 7, 2283-2292.	3.0	65
14	Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorganic and Medicinal Chemistry, 2010, 18, 7515-7521.	3.0	59
15	Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 1598-1604.	6.4	59
16	Computational Strategies in Discovering Novel Non-nucleoside Inhibitors of HIV-1 RT. Journal of Medicinal Chemistry, 2005, 48, 3433-3437.	6.4	58
17	Structure-Based Pharmacophore Identification of New Chemical Scaffolds as Non-Nucleoside Reverse Transcriptase Inhibitors. Journal of Chemical Information and Modeling, 2007, 47, 557-562.	5.4	56
18	A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates. Journal of Medicinal Chemistry, 2016, 59, 16-41.	6.4	56

#	Article	IF	Citations
19	Anti-HIV agents: design and discovery of new potent RT inhibitors. Il Farmaco, 2003, 58, 259-263.	0.9	55
20	Analysis of the full-length integraseâ€“DNA complex by a modified approach for DNA docking. Biochemical and Biophysical Research Communications, 2003, 310, 1083-1088.	2.1	54
21	Inducedâ€Fit Docking Approach Provides Insight into the Binding Mode and Mechanism of Action of HIVâ€1 Integrase Inhibitors. ChemMedChem, 2009, 4, 1446-1456.	3.2	54
22	Re-evolution of the 2-Phenylquinolines: Ligand-Based Design, Synthesis, and Biological Evaluation of a Potent New Class of Staphylococcus aureus NorA Efflux Pump Inhibitors to Combat Antimicrobial Resistance. Journal of Medicinal Chemistry, 2013, 56, 4975-4989.	6.4	51
23	Targeting flavivirus RNA dependent RNA polymerase through a pyridobenzothiazole inhibitor. Antiviral Research, 2016, 134, 226-235.	4.1	49
24	2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction. Journal of Medicinal Chemistry, 2018, 61, 7827-7848.	6.4	46
25	Efficient 3D Database Screening for Novel HIV-1 IN Inhibitors. Journal of Chemical Information and Computer Sciences, 2004, 44, 1450-1455.	2.8	44
26	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 7429-7435.	3.0	43
27	The Versatile Nature of the 6-Aminoquinolone Scaffold: Identification of Submicromolar Hepatitis C Virus NS5B Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 1952-1963.	6.4	43
28	Pyridobenzothiazole derivatives as new chemotype targeting the HCV NS5B polymerase. Bioorganic and Medicinal Chemistry, 2012, 20, 866-876.	3.0	41
29	Docking Studies on a New Human Immodeficiency Virus Integraseâ^'Mgâ^'DNA Complex: Phenyl Ring Exploration and Synthesis of 1H-Benzylindole Derivatives through Fluorine Substitutions. Journal of Medicinal Chemistry, 2009, 52, 569-573.	6.4	40
30	Structure-Based Discovery of Pyrazolobenzothiazine Derivatives As Inhibitors of Hepatitis C Virus Replication. Journal of Medicinal Chemistry, 2013, 56, 2270-2282.	6.4	40
31	Pharmacological Agents Targeting the Cellular Prion Protein. Pathogens, 2018, 7, 27.	2.8	40
32	Pharmacophore Modeling as an Efficient Tool in the Discovery of Novel Noncompetitive AMPA Receptor Antagonists. Journal of Chemical Information and Computer Sciences, 2003, 43, 651-655.	2.8	39
33	Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development. Future Medicinal Chemistry, 2011, 3, 1027-1055.	2.3	39
34	A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2891-2895.	2.2	38
35	Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity. European Journal of Medicinal Chemistry, 2017, 138, 128-139.	5.5	38
36	Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. Retrovirology, 2007, 4, 79.	2.0	37

#	Article	IF	Citations
37	Molecular dynamics studies of the full-length integraseâ€“DNA complex. Biochemical and Biophysical Research Communications, 2005, 336, 1010-1016.	2.1	36
38	Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology, 2010, 7, 21.	2.0	36
39	Binding Mode Prediction of Strand Transfer HIV-1 Integrase Inhibitors Using Tn5 Transposase as a Plausible Surrogate Model for HIV-1 Integrase. Journal of Medicinal Chemistry, 2006, 49, 3994-3997.	6.4	35
40	New Pyrazolobenzothiazine Derivatives as Hepatitis C Virus NS5B Polymerase Palm Site I Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 3247-3262.	6.4	35
41	Computerâ€Aided Design, Synthesis and Validation of 2â€Phenylquinazolinone Fragments as CDK9 Inhibitors with Antiâ€HIVâ€1 Tatâ€Mediated Transcription Activity. ChemMedChem, 2013, 8, 1941-1953.	3.2	32
42	Substituent effects on the enantioselective retention of anti-HIV 5-aryl-?2-1,2,4-oxadiazolines onR, R-DACH-DNB chiral stationary phase. , 1996, 8, 556-566.		31
43	Pharmacological inactivation of the prion protein by targeting a folding intermediate. Communications Biology, 2021, 4, 62.	4.4	30
44	Searching for Novel Inhibitors of the S.â€…aureus NorA Efflux Pump: Synthesis and Biological Evaluation of the 3â€Phenylâ€1,4â€benzothiazine Analogues. ChemMedChem, 2017, 12, 1293-1302.	3.2	28
45	Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. European Journal of Medicinal Chemistry, 2017, 140, 321-330.	5.5	28
46	Pyridobenzothiazolones Exert Potent Anti-Dengue Activity by Hampering Multiple Functions of NS5 Polymerase. ACS Medicinal Chemistry Letters, 2020, 11, 773-782.	2.8	28
47	New 4-[(1-Benzyl-1H-indol-3-yl)carbonyl]-3-hydroxyfuran-2(5H)-ones, Î²-Diketo Acid Analogs as HIV-1 Integrase Inhibitors. Archiv Der Pharmazie, 2007, 340, 292-298.	4.1	27
48	Synthesis, resolution, stereochemistry, and molecular modeling of (R)- and (S)-2-acetyl-1-(4â€²-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline AMPAR antagonists. Bioorganic and Medicinal Chemistry, 2007, 15, 5417-5423.	3.0	27
49	Synthesis and anticonvulsant properties of tetrahydroisoquinoline derivatives. Il Farmaco, 2004, 59, 7-12.	0.9	25
50	Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold. European Journal of Medicinal Chemistry, 2015, 96, 250-258.	5.5	24
51	Functionalized 2,1-benzothiazine 2,2-dioxides as new inhibitors of Dengue NS5 RNA-dependent RNA polymerase. European Journal of Medicinal Chemistry, 2018, 143, 1667-1676.	5.5	24
52	Broad spectrum anti-flavivirus pyridobenzothiazolones leading to less infective virions. Antiviral Research, 2019, 167, 6-12.	4.1	24
53	1,4-Benzothiazine ATP-Sensitive Potassium Channel Openers: Modifications at the C-2 and C-6 Positions. Journal of Medicinal Chemistry, 2013, 56, 4718-4728.	6.4	20
54	A Comprehensive Structural Overview of p38Î± Mitogenâ€Activated Protein Kinase in Complex with ATPâ€Site and Nonâ€ATPâ€Site Binders. ChemMedChem, 2018, 13, 7-14.	3.2	20

#	Article	IF	Citations
55	QSAR Study of Anticonvulsant Negative Allosteric Modulators of the AMPA Receptor. Journal of Medicinal Chemistry, 2004, 47, 1860-1863.	6.4	19
56	Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands. Bioorganic and Medicinal Chemistry, 2014, 22, 4658-4666.	3.0	19
57	Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position. European Journal of Medicinal Chemistry, 2018, 155, 428-433.	5.5	19
58	Synthesis of New Potential HIV-1 Integrase Inhibitors. Heterocycles, 2004, 63, 2727.	0.7	19
59	3D Pharmacophore Models for 1,2,3,4-Tetrahydroisoquinoline Derivatives Acting as Anticonvulsant Agents. Archiv Der Pharmazie, 2006, 339, 388-400.	4.1	18
60	Deciphering the Molecular Recognition Mechanism of Multidrug Resistance Staphylococcus aureus NorA Efflux Pump Using a Supervised Molecular Dynamics Approach. International Journal of Molecular Sciences, 2019, 20, 4041.	4.1	18
61	Preclinical Evaluation of 1H-Benzylindole Derivatives as Novel Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors. Antimicrobial Agents and Chemotherapy, 2008, 52, 2861-2869.	3.2	17
62	A Comprehensive Structural Overview of p38Î± MAPK in Complex with Typeâ€…I Inhibitors. ChemMedChem, 2015, 10, 957-969.	3.2	17
63	Discovery of potent p38Î± MAPK inhibitors through a funnel like workflow combining in silico screening and inÂvitro validation. European Journal of Medicinal Chemistry, 2019, 182, 111624.	5.5	17
64	Accounting for Target Flexibility and Water Molecules by Docking to Ensembles of Target Structures: The HCV NS5B Palm Site I Inhibitors Case Study. Journal of Chemical Information and Modeling, 2014, 54, 481-497.	5.4	16
65	Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode. Biochemical and Biophysical Research Communications, 2007, 363, 554-560.	2.1	15
66	New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action. Bioorganic and Medicinal Chemistry, 2010, 18, 5510-5518.	3.0	15
67	1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors. European Journal of Medicinal Chemistry, 2021, 221, 113494.	5.5	15
68	p38Î± MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening. Molecules, 2015, 20, 15842-15861.	3.8	14
69	The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogenâ€Activated Protein Kinase Inhibitors. Chemical Biology and Drug Design, 2015, 86, 531-545.	3.2	14
70	C-2 phenyl replacements to obtain potent quinoline-based Staphylococcus aureus NorA inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 584-597.	5.2	13
71	Binding modes of noncompetitive AMPA antagonists: a computational approach. Il Farmaco, 2003, 58, 107-113.	0.9	12
72	Response of Feline Immunodeficiency Virus (FIV) to Tipranavir May Provide New Clues for Development of Broad-Based Inhibitors of Retroviral Proteases Acting on Drug-Resistant HIV-1. Current HIV Research, 2008, 6, 306-317.	0.5	12

#	Article	IF	Citations
73	Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors. European Journal of Medicinal Chemistry, 2020, 201, 112420.	5.5	12
74	New trends in the development of AMPA receptor antagonists. Expert Opinion on Therapeutic Patents, 2004, 14, 1199-1213.	5.0	11
75	Structureâ€“Activity Relationships on Cinnamoyl Derivatives as Inhibitors of p300 Histone Acetyltransferase. ChemMedChem, 2017, 12, 1359-1368.	3.2	11
76	Identification of compounds inhibiting prion replication and toxicity by removing PrP^C from the cell surface. Journal of Neurochemistry, 2020, 152, 136-150.	3.9	11
77	Modifications on C6 and C7 Positions of 3-Phenylquinolone Efflux Pump Inhibitors Led to Potent and Safe Antimycobacterial Treatment Adjuvants. ACS Infectious Diseases, 2019, 5, 982-1000.	3.8	10
78	The Compelling Demand for an Effective PrP^C-Directed Therapy against Prion Diseases. ACS Medicinal Chemistry Letters, 2020, 11, 2063-2067.	2.8	10
79	Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. ACS Medicinal Chemistry Letters, 2022, 13, 855-864.	2.8	10
80	Synthesis of new pyridazine derivatives as potential antiâ€HIVâ€1 agents. Journal of Heterocyclic Chemistry, 2009, 46, 1420-1424.	2.6	9
81	Decoding the function of the N-terminal tail of the cellular prion protein to inspire novel therapeutic avenues for neurodegenerative diseases. Virus Research, 2015, 207, 62-68.	2.2	9
82	From Quinoline to Quinazolineâ€Based S. aureus NorA Efflux Pump Inhibitors by Coupling a Focused Scaffold Hopping Approach and a Pharmacophore Search. ChemMedChem, 2021, 16, 3044-3059.	3.2	9
83	Structural Modifications of the Quinolin-4-yloxy Core to Obtain New Staphylococcus aureus NorA Inhibitors. International Journal of Molecular Sciences, 2020, 21, 7037.	4.1	8
84	Structural Modification of Diketo Acid Portion in 1H-Benzylindole Derivatives HIV-1 Integrase Inhibitors. Heterocycles, 2009, 78, 947.	0.7	7
85	Tumour cell population growth inhibition and cell death induction of functionalized 6â€aminoquinolone derivatives. Cell Proliferation, 2015, 48, 705-717.	5.3	6
86	Bicyclic octahydrocyclohepta[b]pyrrol-4(1 H)one derivatives as novel selective anti-hepatitis C virus agents. European Journal of Medicinal Chemistry, 2016, 122, 319-325.	5.5	6
87	Co-crystal structure determination and cellular evaluation of 1,4-dihydropyrazolo[4,3-c] [1,2] benzothiazine 5,5-dioxide p38Î± MAPK inhibitors. Biochemical and Biophysical Research Communications, 2019, 511, 579-586.	2.1	6
88	Sustainable, three-component, one-pot procedure to obtain active anti-flavivirus agents. European Journal of Medicinal Chemistry, 2021, 210, 112992.	5.5	6
89	A Smallâ€Molecule Inhibitor of Prion Replication and Mutant Prion Protein Toxicity. ChemMedChem, 2017, 12, 1286-1292.	3.2	5
90	New Insights on KCa3.1 Channel Modulation. Current Pharmaceutical Design, 2020, 26, 2096-2101.	1.9	4

#	Article	IF	Citations
91	Pharmacophore Modeling as an Efficient Tool in the Discovery of Novel Noncompetitive AMPA Receptor Antagonists.. ChemInform, 2003, 34, no.	0.0	0
92	anti-HIV Agents: Design and Discovery of New Potent RT Inhibitors.. ChemInform, 2003, 34, no.	0.0	0
93	Synthesis and Anticonvulsant Properties of Tetrahydroisoquinoline Derivatives.. ChemInform, 2004, 35, no.	0.0	0
94	Efficient 3D Database Screening for Novel HIV-1 IN Inhibitors.. ChemInform, 2004, 35, no.	0.0	0
95	Maria Letizia Barreca on hepatitis C virus treatment and control. Future Medicinal Chemistry, 2016, 8, 7-9.	2.3	0